Institut National de la Santé et de la Recherche Médicale (INSERM);Centre National de la Recherche Scientifique (CNRS);Universite Claude Bernard Lyon 1;Sorbonne Université
The present invention relates to new N1-and N7-substituted sibiriline derivatives of the following general formula (I): (I) or a pharmaceutically acceptable salt and/or solvate thereof, notably for use as drug, in particular for use as inhibitor of cellular necroptosis. The present invention also relates to a pharmaceutical composition comprising such a compound and processes to prepare such a compound. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation.
